High-dose Radiotherapy Systems Market

High-dose Radiotherapy Systems Market Outlook (2023 to 2033)

The global high-dose radiotherapy systems market is projected to increase from a valuation of US$ 2.7 billion in 2022 to US$ 4 billion by the end of 2033, expanding at a CAGR of 3.9% along the way.

Technological innovation is the key driver for the rising demand for high-dose radiotherapy systems, as they help in improving the precision and applicability of radiation therapy. Use of radiation therapy for treating a wider range of cancer cases is rising.

Radiation therapy (RT) is the most common non-surgical treatment option for lung cancer, and it plays an essential role in the multidisciplinary management of thoracic cancers. Technological advancements in radiotherapy procedures and new fractionation models have improved long-term disease control and decreased radiation-related adverse effects.

Intensity-modulated radiotherapy (IMRT), stereotactic radiotherapy, image-guided radiotherapy (IGT), and particle therapy have made it easier to plan treatments, accurately delineate tumors, and estimate doses for successful, personalized treatment. This is likely to boost the usage of high-dose radiation systems for the treatment of cancer in the near future.

Launch of new and innovative radiotherapy systems supports market growth as these products are more cost-effective and compact than the previously installed equipment. Advanced hardware and software systems allow newer and higher standards of care.

• The global market expanded at a CAGR of 3.1% from 2017 to 2022.
• LINAC devices dominated the market with a value contribution of US$ 2.2 billion in 2022.
• High-dose radiotherapy systems accounted for 33.1% share of the global radiotherapy market in 2022.

Top market players are consistently providing their clients with the latest and most effective technologies, thus fueling market growth.

• Elekta's MR-Linac, the Elekta Unity system, obtained a CE marking in October 2022, enabling its use in radiation therapy for cancer treatment.
• In March 2022, Zeiss introduced the Intrabeam system in India, offering intraoperative radiation therapy (IORT) for patients diagnosed with early-stage breast cancer.

Upgraded software versions also aim at continuously improving the workflow in radiation therapy, resulting in better integration and optimization with treatment systems. Greater volumes of data can be collected, stored, and analyzed using these software systems.

What are the Factors Creating Lucrative Opportunities for High-dose Radiotherapy System Manufacturers?

“Technological Advancements and Increasing Demand for Effective Radiotherapy Solutions”

Joint mergers and partnerships between market players offer lucrative opportunities for manufacturers of radiotherapy systems and software products. Both hardware and software companies are accelerating initiatives in this direction as part of their growth strategy to improve technologies, reduce costs, and expand their commercial reach.

As a result of recent technological developments, radiotherapy is now more effective, resulting in improved quality of life and more effective management of cancer patients. Various notable advancements have significantly enhanced tumor dose distribution and minimized toxicity in healthy tissue in the field of radiation therapy. These include the introduction of the multileaf collimator, integration of imaging technologies such as computed tomography (CT) and positron emission tomography (PET), utilization of advanced dose calculation algorithms, and the development of advanced delivery techniques.

Integration of artificial intelligence and radiotherapy systems and software is opening up profitable opportunities for high-dose radiotherapy system manufacturers. Technological advancements in recent years have opened up new market potential across various industry verticals, particularly in the healthcare industry, where different technologies find diverse applications. Artificial intelligence is one of the prime technologies resulting in the improved efficiency of treatment planning systems.

Analysis of huge data available about patients and their health issues is a time-consuming and complex task for radiologists to deliver accurate treatment. By combining artificial intelligence with radiation therapy software, radiologists can analyze patient data in less time. AI can help in classifying cancer types using innovative techniques, such as gene masking. Advancements in the hardware and software components of radiation therapy systems can help replace conventional machines to deliver higher standards of care.

Expansion of radiation therapy capacity is driven by the rising incidence of cancer. There is a substantial demand for cost-effective equipment, making the launch of reasonably priced equipment a significant opportunity for companies to increase their market share.

What are the Factors Limiting Market Expansion to Some Extent?

“High Equipment Cost and Wide Availability of Alternative Therapies”

High cost of radiotherapy systems is a significant limiting factor for market growth. External beam radiation therapy (EBRT) machines cost US$ 2.5 million and proton therapy systems cost more than US$ 40 million. Along with the equipment cost, there is a huge amount spent on establishing a treatment room as well.

Expenses associated with radiotherapy equipment increase the cost of the services, rendering them inaccessible for a significant portion of patients, especially those in low- and middle-income countries.

Availability of other cancer treatment types such as chemotherapy and surgery and the advancement in these procedures also restrict the demand for radiation therapy. The effective advancement of alternative cancer treatments, such as immunotherapy, and improved efficacy of newly developed treatments or current medications can restrict the adoption of high-dose radiotherapy systems. At present, there is a lot of emphasis on creating personalized medicines for particular cancer treatments, which also limits market expansion.

Country-wise Insights

What is the Reason for the Dominance of the United States in the Global Market?

“Increasing Utilization of Radiotherapy for Cancer Treatment”

The United States dominated the global market generating revenue of US$ 846.1 million in 2022. The market in the United States is driven by the increasing utilization of radiotherapy in cancer treatment and management.

• The Organization for Economic Co-operation and Development (OECD) reported that in 2019, there were 11.7 radiotherapy machines per 100,000 people, up from 11.5 in 2018.

The country is expected to dominate the global market in the future as well due to the rising incidence of cancer, growing healthcare expenditure, and increasing research initiatives to develop technologically advanced systems and software. Presence of key players and favorable government initiatives are also expected to contribute to market growth.

How are Sales of High-dose Radiotherapy Systems Faring in Germany?

“Rising Prevalence of Cancer and Availability of Advanced Radiotherapy Procedures”

Germany dominated the European market and accounted for 5.9% of the global market share in 2022.

Germany is emerging as a prominent market for high-dose radiotherapy systems due to several factors. First, the increasing prevalence of cancer in Germany is driving the demand for radiotherapy systems. Second, technological advancements in radiotherapy, such as improved imaging techniques and precision delivery systems, are creating opportunities for the development of more effective and targeted treatments.

• According to Globocan 2020 data, breast cancer, prostate cancer, and lung cancer collectively account for over 30% of total cancer cases in Germany, making them the most common types of cancer in the country.

Rising prevalence of cancer in Germany is expected to result in greater utilization of high-dose radiotherapy systems in the treatment and management of the disease.

What is the Demand Projection for High-dose Radiotherapy Systems in China?

“Growing Cancer Incidence Driving Demand for Specialized High-Dose Radiotherapy Systems to Address Unique Cancer Profile”

China accounted for 5.8% share of the global market in 2022.

With its large population and the highest number of new cancer cases and deaths in the world, China's substantial cancer incidence generates a substantial demand for high-dose radiotherapy systems.

China has a unique cancer profile, with certain types of cancer, such as lung, colorectal, and stomach cancer, being more prevalent as compared to other regions. This necessitates the development of radiotherapy systems that can effectively treat specific cancer types.

• As per World Cancer Research Fund International, China accounts for a substantial portion of the global cancer burden. In 2020, China recorded over 4.5 million newly diagnosed cancer cases, resulting in over 3 million cancer-related deaths.

Category-wise Insights

Why are LINAC Devices in High Demand Globally?

“Wide Accessibility of LINAC Devices Driving Their Adoption”

The LINAC devices segment dominated the global market and accounted for a valuation of US$ 2.2 billion in 2022.

LINAC devices, being a popular form of external beam radiation therapy for cancer patients, are widely utilized for cancer treatment worldwide. This widespread adoption highlights the accessibility of LINAC equipment across the globe. LINAC devices can carry out IMRT (intensity-modulated radiation therapy), SRS (stereotactic radiosurgery), SBRT (stereotactic body radiation therapy), VMAT (volumetric modulated arc therapy), and IGRT (image-guided radiation therapy) on any part of the body.

Because of the adaptability of LINAC devices, they can be used to treat a variety of malignancies. As a result, these devices are being used extensively all over the world.

Which End User Makes a Significant Contribution to Global Market Expansion?

“High Demand for Radiotherapy Systems in Cancer Treatment Centers and Clinics Due to Favorable Reimbursement Policies”

Cancer treatment centers & clinics held a market share of 47.5% in 2022. Cancer treatment centers and clinics are the primary healthcare settings where patients with cancer receive treatment.

In areas with a high cancer incidence, there is a crucial demand for radiotherapy systems to address the treatment needs. Moreover, cancer treatment centers and clinics in these settings often offer favorable reimbursement policies, facilitating easier access to radiotherapy treatments for patients.

Competition Landscape

The high-dose radiotherapy systems market is highly competitive and consists of a few leading players. Manufacturers are offering a range of radiotherapy systems, including linear accelerators (LINACs) and proton therapy systems. Leading players are implementing partnership agreements and product launches to tap into new markets and expand their reach.

Key market developments include:

• In June 2021, to improve holistic and personalized cancer care through precision oncology technologies, Elekta and Philips signed agreements to strengthen their existing strategic partnership.
• In June 2020, Accuray announced the release of the CyberKnife® S7TM System. This is an innovative tool combining real-time motion tracking and synchronization as well as advanced precision and speed for all other radiation therapy systems, including stereotactic body radiation therapy (SBRT) treatments and stereotactic radiosurgery (SRS).

Similarly, the team at Persistence Market Research has tracked recent developments related to companies manufacturing high-dose radiotherapy systems, which are available in the full report.

High-dose Radiotherapy Systems Industry Report Scope

High-dose Radiotherapy Systems Industry Research Segmentation

By Product:

• LINAC Devices
• Proton Therapy Devices
• Brachytherapy

By End User:

• Hospitals
• Cancer Treatment Centers & Clinics
• Research Centers

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

To know more about delivery timeline for this report Contact Sales